Advancing the science of cellular metabolism to create novel and transformative medicines

Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need.  We are propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do.

Leadership Team

David-Alexandre C. Gros, M.D.

Co-Founder, President, and
Chief Executive Officer

Bio +

David-Alexandre C. Gros, M.D.

Co-Founder, President, and
Chief Executive Officer

D.A. Gros is Co-Founder, President, and Chief Executive Officer of Imbria Pharmaceuticals. D.A. has extensive experience in building and financing bio-pharmaceutical companies as well as developing and executing growth strategies. He joined Imbria from Neurocrine Biosciences where he was President, Chief Operating Officer and acting Chief Financial Officer. Prior to Neurocrine, he served as Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals, and as Chief Strategy Officer of Sanofi.  Before joining Sanofi, D.A. held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. He holds an MD from Johns Hopkins University School of Medicine, an MBA from Harvard Business School, and an AB from Dartmouth College.

X

Jai Patel, M.B.B.S. (Hons.), M.R.C.P. (U.K.)

Chief Medical Officer

Bio +

Jai Patel, M.B.B.S. (Hons.), M.R.C.P. (U.K.)

Chief Medical Officer

Jai Patel is Chief Medical Officer of Imbria Pharmaceuticals. He has over 25 years of experience in Phase I to IV clinical drug development in the US and Europe in the cardiovascular and metabolism therapeutic area.  Prior to Imbria, he was the Chief Medical Officer at Enterome and NephroGenex. Jai spent over 20 years at GlaxoSmithKline in positions of increasing responsibility, serving as Vice President across multiple R&D functions including Clinical Development, Medical Affairs and Regulatory Affairs. Jai received a Bachelor of Science in Experimental Pathology from the University of London and completed his medical training at St. Bartholomew’s Hospital and Kings College Hospitals, University of London. He is a member of the Royal College of Physicians (UK).

X

Heidi Henson

Chief Financial Officer

Bio +

Heidi Henson

Chief Financial Officer

Heidi Henson is Chief Financial Officer of Imbria Pharmaceuticals. She has over 25 years of financial operations experience with both public and private companies. Prior to Imbria, she was Chief Financial Officer and Secretary of Kura Oncology and Chief Financial Officer of Wellspring Biosciences and its parent company Araxes Pharma. Heidi also served as Vice President, Finance at Intellikine until its acquisition by Takeda. Before joining Intellikine, Heidi served as an independent financial consultant assisting with various start-up activities for early stage companies, SEC reporting and Sarbanes-Oxley implementation and compliance. She began her career in auditing at PricewaterhouseCoopers LLP. Heidi received a Bachelor’s of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive) in the state of California.

X

Ebun Garner, J.D.

Chief Legal Officer

Bio +

Ebun Garner, J.D.

Chief Legal Officer

Ebun Garner is the Chief Legal Officer of Imbria Pharmaceuticals.  Ebun has represented publicly traded life science companies for over 20 years, in which he has served as “in-house” counsel for the past 14 years.  Prior to Imbria he was Assistant General at Neurocrine Biosciences (Nasdaq:NBIX), where he was the primary legal support for all non-commercial legal matters at Neurocrine, and supported Neurocrine’s public company reporting.  Prior to Neurocrine, Ebun served as General Counsel, Senior Vice President and Corporate Secretary of Alphatec Spine (Nasdaq:ATEC).  Prior to Alphatec, Ebun was a corporate associate in the New York office of the law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  Ebun has a B.A. in Economics from the University of Pennsylvania, and a J.D. from New York University School of Law.

X

Paul Chamberlin, M.D.

Head of Clinical Development

Bio +

Paul Chamberlin, M.D.

Head of Clinical Development

Paul Chamberlin is Head of Clinical Development of Imbria Pharmaceuticals. Paul has significant experience in cardiovascular research and development. He joined Imbria from Ironwood Pharmaceuticals where he was Senior Medical Director. Prior to Ironwood, he held leadership positions at multiple start-up biotechnology companies. He was part of the launch team at Ventrix, serving as Chief Medical Officer; was VP of Medical Development at Sequel Pharmaceuticals; and led research and clinical development of cardiac drugs for the treatment of heart failure and atrial fibrillation at NovaCardia. Before NovaCardia, Paul served in various positions of increasing responsibility at EPIX Pharmaceuticals, including as Executive Medical Director. He started his career in healthcare strategy consulting at Arthur D. Little and the biotechnology division of Rhone-Poulenc-Rorer (now Sanofi). Paul holds an MD from Boston University an a BA in Biology from the University of Pennsylvania.

X

Board of Directors

Pieter Boelhouwer, J.D.

Managing Director of Strategy and Operations at RA Capital Management

Bio +

Pieter Boelhouwer, J.D.

Managing Director of Strategy and Operations at RA Capital Management

Pieter Boelhouwer is a Managing Director of Strategy and Operations at RA Capital Management. Pieter’s primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. He held senior management positions at two successful start-up companies that were acquired and has over 14 years of experience investing in the global healthcare sector, both as a Partner and Managing Director at Matrix Capital Management and as a General Partner and Managing Director at Ayer Capital Management, a healthcare-focused hedge fund. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. He holds a BA from Trinity College and a JD from Yale Law School.

X

David-Alexandre C. Gros, M.D.

Co-Founder, President, and
Chief Executive Officer

Bio +

David-Alexandre C. Gros, M.D.

Co-Founder, President, and
Chief Executive Officer

D.A. Gros is Co-Founder, President, and Chief Executive Officer of Imbria Pharmaceuticals. D.A. has extensive experience in building and financing bio-pharmaceutical companies as well as developing and executing growth strategies. He joined Imbria from Neurocrine Biosciences where he was President, Chief Operating Officer and acting Chief Financial Officer. Prior to Neurocrine, he served as Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals, and as Chief Strategy Officer of Sanofi.  Before joining Sanofi, D.A. held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. He holds an MD from Johns Hopkins University School of Medicine, an MBA from Harvard Business School, and an AB from Dartmouth College.

X

Andrew Levin, M.D., Ph.D.

Co-Founder and Founding
Chief Scientific Officer

Bio +

Andrew Levin, M.D., Ph.D.

Co-Founder and Founding
Chief Scientific Officer

Andrew Levin is Co-Founder and was the founding Chief Scientific Officer of Imbria Pharmaceuticals. Since joining RA Capital Management in 2015, Andrew has been spearheading drug discovery efforts that have led to the formation of several companies and is also a Managing Director on the Investment Team. Prior to joining RA Capital, he was a Vice President at H.I.G. BioVentures and previously served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

X

Gianluca Pirozzi, M.D., Ph.D.

Head of Rare Disease Drug Development and Head of Translational Gene Therapy at Sanofi-Genzyme

Bio +

Gianluca Pirozzi, M.D., Ph.D.

Head of Rare Disease Drug Development and Head of Translational Gene Therapy at Sanofi-Genzyme

Gianluca Pirozzi is currently Head of Rare Disease Drug Development and Head of Translational Gene Therapy at Sanofi-Genzyme. He is also Scientific Advisor for the Smith-Magenis-Syndrome (SMS) Research Foundation, a non-profit organization for the treatment of SMS, a rare chromosomal syndrome. Prior to his current role, was the Global Project Head for Dupixent (anti-IL4R mAb) for 5 years, leading the program from proof-of-concept to approval in 7 indications. Gianluca has been with Sanofi since 2005 and has also worked in Global Pharmacovigilance & Risk Management as well as the full spectrum of clinical development in the Inflammation & Immunology therapeutic area. He started his career in industry as a medical advisor for Servier Laboratories. Gianluca holds an MD from Università Campus Bio-Medico di Roma and a PhD in Immunology from Sapienza Università di Roma. He completed a Post-Doc in Immunology at the Pasteur Institute in Paris, France.

X